Cover Image
市場調查報告書

關注市場分析:青光眼

Market Spotlight: Glaucoma

出版商 Datamonitor Healthcare 商品編碼 570529
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:青光眼 Market Spotlight: Glaucoma
出版日期: 2018年01月17日 內容資訊: 英文 53 Pages
簡介

本報告提供青光眼的市場調查,疾病的背景、概要,開發平台藥物及已上市藥物趨勢,臨床試驗狀況,法律規章、核准相關趨勢,專利資訊,盛行率的10年預測,授權、收購等的交易趨勢,主要藥物的收益預測等彙整資料。

要點

疾病的背景

  • 分類

治療

  • 眼藥
  • 口服投藥

流行病學

開發平台藥物

已上市藥物

  • 核准:各國

今後的主要活動

主要的法律規章相關意活動

  • Aerie
  • MIXiii Biomed 2017
  • Bausch & Lomb/Nicox
  • Regeneron、Ocular
  • 新的聯合治療
  • 美國的核准趨勢分析

授權、收購等的交易

  • 參天製藥、TwoXAR
  • 大塚製藥/Acucela
  • Alcon

父母專利

商機

臨床試驗環境

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0176499

This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Eye drops
  • Oral medications
  • EPIDEMIOLOGY

MARKETED DRUGS

  • Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned
  • Glaukos Submits PMA For iStent, Second-Generation MIGS Device For Treating Glaucoma
  • Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
  • MIXiii Biomed 2017: Aging, Technology & Robotics In The Digital World
  • Bausch & Lomb/Nicox Eye Drug Resubmission Is Assigned August Review Goal
  • Aerie's Rhopressa Lands At FDA Again
  • FDA Seeks Plant Clean-Up Before Approving Eye Drug
  • Aerie Grounds Rhopressa
  • Regeneron Partnering With Ocular May Provide Needed Tech Validation
  • New Combinations
  • US Approvals Analysis

LICENSING AND ASSET ACQUISITION DEALS

  • Santen, TwoXAR Collaborate In Ophthalmics
  • Otsuka/Acucela (No Deal)
  • Alcon Puts Money Where Mouth Is With Glaucoma Device Buy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Prevalence trends in glaucoma, 2016-25
  • Figure 2: Prevalent cases of glaucoma, by region, 2017
  • Figure 3: Overview of pipeline drugs for glaucoma in the US
  • Figure 4: Pipeline drugs for glaucoma, by company
  • Figure 5: Pipeline drugs for glaucoma, by drug type
  • Figure 6: Pipeline drugs for glaucoma, by classifications
  • Figure 7: Key upcoming events in glaucoma
  • Figure 8: Licensing and asset acquisition deals in glaucoma
  • Figure 9: Parent patents in glaucoma
  • Figure 10: Clinical trials in glaucoma
  • Figure 11: Top 10 drugs for clinical trials in glaucoma
  • Figure 12: Top 10 companies for clinical trials in glaucoma
  • Figure 13: Trial locations in glaucoma
  • Figure 14: Glaucoma trials status
  • Figure 15: Glaucoma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of glaucoma, 2016-25
  • Table 2: Prevalence proportions in glaucoma, 2016-25
  • Table 3: Marketed drugs for glaucoma
  • Table 4: Approvals by country for glaucoma
  • Table 5: Pipeline drugs for glaucoma in the US
  • Table 6: Historic global sales, by drug ($m), 2012-16
  • Table 7: Forecasted global sales, by drug ($m), 2017-22
Back to Top